R.J.M. reports a consulting or advisory role for Pfizer, Novartis, Eisai, Exelixis, Merck, Genentech, Incyte, Lilly and Roche; research funding (institutional) from Pfizer, Bristol-Myers Squibb, Eisai, Novartis, Genentech and Roche; and reimbursement for travel, accommodations and expenses from Bristol-Myers Squibb. P.B.R. is an employee of Pfizer. T.P. reports personal fees from AstraZeneca, Bristol-Myers Squibb, Eisai, Roche/Genentech, Seattle Genetics, MSD, GSK, Pfizer, Astellas, Merck Serono, Novartis, Ferring and Exelixis and grants from AstraZeneca and Roche outside the submitted work. L.A. reports a consulting/advisory role (institutional) for Novartis, Amgen, Bristol-Myers Squibb, Ipsen, Roche, Pfizer, Astellas Pharma, Merck, MSD, AstraZeneca, Exelixis, Corvus Pharmaceuticals, Peloton therapeutics and research funding from Bristol-Myers Squibb. J.B.H. reports grants and institutional fees from Bristol-Myers Squibb, MSD, Novartis and Neon Therapeutics and institutional fees from Pfizer, Roche/Genentech, Bayer, Amgen, Immunocore, Sanofi, Seattle Genetics, Gadeta BV, GSK, Celsius Therapeutics and AstraZeneca/Medimmune outside the submitted work. J.L. reports personal fees from Eisai, Roche/Genentech, Secarna, Pierre Fabre, EUSA Pharma, MSD, GSK and Kymab and grants and personal fees from Bristol-Myers Squibb, Pfizer and Novartis outside the submitted work. X.J.M. and K.A.C. are employees of Pfizer. M.U. has nothing to disclose. S.P. reports a consulting/advisory role for Genentech, Aveo, Eisai, Roche, Pfizer, Novartis, Exelixis, Ipsen, Bristol-Myers Squibb and Astellas. B.A. reports personal fees from Amgen and Ferring, grants from Ipsen and grants and personal fees from Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, MSD, Pfizer, Roche and Sanofi outside the submitted work. G.G. and K.P. have nothing to disclose. M.T.C. reports personal fees from Eisai Medical Research, EMD Serono, Apricity Health, Pfizer, Genentech and Taiho outside the submitted work. J.L.L. reports grants and personal fees from Pfizer, other fees from Eisai and personal fees from Ipsen, Janssen, Sanofi Aventis, Novartis, Astellas and Bristol-Myers Squibb outside the submitted work. S.H., X.W., W.Z., J.W., A.C., A.d.P. and A.C.D. are employees of Pfizer. T.K.C. reports grants received during the conduct of the study from Pfizer and personal fees received outside the conduct of the study from Agensys, Alexion, Alligent, American Society of Clinical Oncology, Analysis Group, AstraZeneca, Bayer, Bristol-Myers Squibb, Celldex, Cerulean, Clinical Care Options, Corvus, Dana-Farber Cancer Institute, EMD Serono, Eisai, Exelixis, Foundation Medicine, Genentech/Roche, GlaxoSmithKline, Harborside Press, Heron, Ipsen, Kidney Cancer Association, Kidney Cancer Journal, L-path, Lancet Oncology, Lilly, Merck, Michael J. Hennessy Associates, National Comprehensive Cancer Network, Navinata Health, New England Journal of Medicine, Novartis, Peloton Therapeutics, Pfizer, PlatformQ Health, Prometheus Laboratories, Sanofi/Aventis, Seattle Genetics/Astellas, and UpToDate; grants received outside the conduct of the study were from AstraZeneca, Bayer, Bristol-Myers Squibb, Calithera, Cerulean, Corvus, Eisai, Exelixis, Foundation Medicine, Genentech/Roche, GlaxoSmithKline, Ipsen, Merck, Novartis, Peloton Therapeutics, Pfizer, Prometheus Laboratories, Takeda, and Tracon; and medical writing and editorial assistance were provided by ClinicalThinking, Envision Pharma Group, Fishawack Group of Companies, Health Interactions and Parexel and funded by pharmaceutical companies.